209 related articles for article (PubMed ID: 31428960)
1. Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
Levinsky NC; Morris MC; Wima K; Sussman JJ; Ahmad SA; Cloyd JM; Kimbrough C; Fournier K; Lee A; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Zaidi MY; Staley CA; Maithel SK; Leiting J; Grotz T; Lambert L; Hendrix RJ; Ronnekleiv-Kelly S; Pokrzywa C; Raoof M; Eng OS; Johnston FM; Greer J; Patel SH
J Gastrointest Surg; 2020 Jan; 24(1):155-164. PubMed ID: 31428960
[TBL] [Abstract][Full Text] [Related]
2. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
4. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
[TBL] [Abstract][Full Text] [Related]
5. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.
Turner KM; Morris MC; Delman AM; Hanseman D; Johnston FM; Greer J; Walle KV; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Maduekwe U; Kothari A; Staley CA; Maithel SK; Lambert LA; Kim AC; Cloyd JM; Wilson GC; Sussman JJ; Ahmad SA; Patel SH
J Gastrointest Surg; 2022 Dec; 26(12):2569-2578. PubMed ID: 36258061
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
[TBL] [Abstract][Full Text] [Related]
7. Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.
Wagner PL; Austin F; Maduekwe U; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2013 Apr; 20(4):1056-62. PubMed ID: 23456385
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Munoz-Zuluaga C; Studeman K; Nieroda C; Sittig M; King MC; Sipok A; Gushchin V
Ann Surg Oncol; 2020 Jan; 27(1):179-187. PubMed ID: 31646450
[TBL] [Abstract][Full Text] [Related]
9. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
11. Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival.
Solomon D; DeNicola N; Feingold D; Liu PH; Aycart S; Golas BJ; Sarpel U; Labow DM; Magge DR
J Surg Oncol; 2019 May; 119(6):758-765. PubMed ID: 30650185
[TBL] [Abstract][Full Text] [Related]
12. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
13. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma.
Flood MP; Roberts G; Mitchell C; Ramsay R; Michael M; Heriot AG; Kong JC
Asia Pac J Clin Oncol; 2024 Feb; 20(1):32-40. PubMed ID: 36880398
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
[TBL] [Abstract][Full Text] [Related]
15. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
[TBL] [Abstract][Full Text] [Related]
16. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
[TBL] [Abstract][Full Text] [Related]
17. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
18. Impact of signet ring cells on overall survival in peritoneal disseminated appendix cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Shamavonian R; Lansom JD; Karpes JB; Alzahrani NA; Morris DL
Eur J Surg Oncol; 2021 Jan; 47(1):194-198. PubMed ID: 33272738
[TBL] [Abstract][Full Text] [Related]
19. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma.
Chua TC; Pelz JO; Kerscher A; Morris DL; Esquivel J
Ann Surg Oncol; 2009 Oct; 16(10):2765-70. PubMed ID: 19641972
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
